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Abstract The efficacy of combined treatment in active
acromegaly with both long-acting somatostatin analogs
(SRIF) and pegvisomant (PEG-V) has been well estab-
lished. The aim was to describe the PEG-V dose reductions
after the conversion from daily PEG-V to combination
treatment. To clarify the individual beneficial and adverse
effects, in two acromegaly patients, who only normalized
their insulin like growth factor (IGF-I) levels with high-
dose pegvisomant therapy. We present two cases of a 31
and 44 years old male with gigantism and acromegaly that
were controlled subsequently by surgery, radiotherapy,
SRIF analogs and daily PEG-V treatment. They were
converted to combined treatment of monthly SSA and
(twice) weekly PEG-V. High dose SSA treatment was
added while the PEG-V dose was decreased during carful
monitoring of the IGF-I. After switching from PEG-V
monotherapy to SRIF analogs plus pegvisomant combina-
tion therapy IGF-I remained normal. However, the neces-
sary PEG-V dose, to normalize IGF-I differed significantly
between these two patients. One patient needed twice
weekly 100 mg, the second needed 60 mg once weekly on
top of their monthly lanreotide Autosolution injections of
120 mg. The weekly dose reduction was 80 and 150 mg.
After the introducing of lanreotide, fasting glucose and
glycosylated haemoglobin concentrations increased. Dia-
betic medication had to be introduced or increased. No
changes in liver tests or in pituitary adenoma size were
observed. In these two patients, PEG-V in combination
with long-acting SRIF analogs was as effective as PEG-V
monotherapy in normalizing IGF-I levels, although sig-
nificant dose-reductions in PEG-V could be achieved.
However, there seems to be a wide variation in the
reduction of PEG-V dose, which can be obtained after
conversion to combined treatment.
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Introduction
Pegvisomant, a growth hormone (GH) receptor antagonist
is a highly effective medical therapy for acromegaly.
Studies have reported on high efficacy of pegvisomant
(PEG-V), alone or in combination with somatostatin ana-
logs (SRIF) of [90% to control insulin like growth factor
(IGF-I) [1–4]. The necessary PEG-V dose to control IGF-I
seems to be lower during combination therapy than with
PEG-V alone [2, 5]. The combination treatment is probably
therefore more effective at equal weekly dose than PEG-V
alone [2, 3, 5]. There is a necessity to control IGF-I and GH
has been well established since this will predict mortality
[6, 7]. So combined treatment seems to be an attractive
option.
We present two cases of acromegaly patients who were
controlled during daily, mono-therapy of PEG-V and were
converted to combination treatment.
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Subjects and methods
Case report
Case A
A 31-years-old man was diagnosed with diabetes and
gigantism since 1995, with a random GH of 220 mU/l and an
IGF-I 4.5 times the upper limit of normal (9 ULN). A macro
adenoma of 3 cm with suprasellar extension, impingement
of the chiasm and invasion in the left cavernous sinus which
was assessed by the Magnetic Resonance Imaging (MRI). In
1996, the initial treatment was transsphenoidal surgery.
Pathologist reported a pituitary adenoma which a positive
immunohistochemical staining for GH. Postoperative the
GH levels and IGF-I levels remained uncontrolled
(Table 1). In 1997, 4 times daily subcutaneous injection of
Octreotide 300 lg was started and later converted to
Octreotide LAR 30 mg monthly. In 1997, additional radio-
therapy of 45 Gy in 25 fractions was given. In 1998, despite
all these efforts IGF-I and GH remained elevated while other
anterior pituitary hormones became deficient, which needed
replacement therapy. Therefore, this patient was switched to
pegvisomant therapy. Octreotide LAR was stopped in 1998
and daily PEG-V was increased up to 40 mg daily until
IGF-I was within the age adjusted normal limits [4]. In
October 2006 Lanreotide autosolution (LAN) was added and
PEG-V was decreased in dose and frequency according to
protocol. On pituitary MRI prior to the introduction of the
LAN a remnant (8 mm) of the adenoma was present in and
around left cavernous sinus.
Case B
A 44-year-old man was diagnosed with acromegaly and
osteoporosis since 1994. At the time of diagnose random
GH serum levels were around 120 mU/l while IGF-I serum
levels were around 3.5 9 ULN. On MRI, he had a pituitary
tumor of 2-cm with suprasellar extension, but without
impingement of the chiasm and possible invasion of the
right cavernous sinus. In 1994 he underwent transsphenoi-
dal surgery. A tumor specimen revealed positive immuno-
histochemical staining for GH. After surgery, he was treated
with radiotherapy (42 Gray in 32 fractions). After surgery
and RT GH serum levels dropped to around 17 lg/l. Three
months post surgery IGF-I serum levels were decreased to
3.0 9 ULN. In 1995, Octreotide was started (100 lg t.i.d.)
and converted to monthly Octreotide LAR 40 mg in 1998.
Although he developed panhypopituitarism and GH levels
normalized, IGF-I levels remained elevated, around
1.9 9 ULN (Table 1). In 2003, Octreotide LAR therapy
was switched into PEG-V monotherapy. Daily PEG-V
dosages of 30 mg PEG-V were necessary to decrease IGF-I
levels to within the age adjusted normal limits. In Marche
Table 1 Biochemical parameters and medication of both patients before and during combination therapy
Patient A date 1998 2000 2002 2003 Jan-07 Apr-07 Jul-07 Oct-07
Acromegaly
medication
Octreotide
LAR 30
PEG-V 40
OD
PEG-V 40
OD
PEG-V 40
OD
LAN 120
PEG-V 70
mg TW
LAN 120
PEG-V 80
mg TW
LAN 120
PEG-V 100
mg TW
LAN 120
PEG-V 100
mg TW
GH lg/l 42 N/A N/A N/A N/A N/A N/A N/A
IGF-I ULN (nmol/l) 1.9 (73,9) 0.98 (39.3) 0.93 (37.3) 0.93 (37.0) 1.3 (55.7) 1.0 (40.9) 0.8 (31.4) 0.5 (20.8)
HbA1c 6.9 6.4 6.1 6.2 8.4 8.7 9.0 7.7
Fasting glucose 7.3 4.9 5.9 6.5 8.0 9.4 5.7 3.8
DM medication INN TD 5 INN TD 5 INN TD 5 INN TD 5 INN TD 5 INN TrD 5 INN TrD 5 INN TD 5
Glargin 48
IE OD
Patient B date 2003 2004 2005 2006 Jun-07 Sep-07 Dec-07 Mar-07
Acromegaly medication Octreotide
LAR 40
PEG-V 30
OD
PEG-V 30
OD
PEG-V 30
OD
LAN 120
PEG-V 50
mg TW
LAN 120
PEG-V 80
mg OW
LAN 120
PEG-V 60
mg OW
LAN 120
PEG-V 60
mg OW
GH lg/l 2.3 N/A N/A N/A N/A N/A N/A N/A
IGF-I ULN (nmol/l) 1.93 (67.5) 0.82 (28.6) 0.96 (33.6) 0.96 (32.9) 0.3 (12.1) 0.5 (16.6) 0.9 (31.7) 0.8 (29.8)
HbA1c N/A 6.6 6.3 6.4 6.9 7.8 8.9 7.4
Fasting glucose 5.7 4.0 4.6 5.0 6.9 10.7 8.9 7.8
DM medication none none none none none MT 500 TD MT 850 TrD MT 850 TrD
LAN Lanreotide Autosolution (mg), PEG-V Pegvisomant (mg), OD Once Daily, OW Once Weekly, TW Twice Weekly, TD Twice Daily,
TrD Trice Daily, INN glibenclamide (mg), MT metformin (mg) and N/A
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2007, LAN was added and PEG-V was decreased in dose
and frequency. On pituitary MRI prior to the introduction of
the LAN, a small (5 mm) remnant of the adenoma was
present close to the right cavernous sinus.
Methods
After monthly LAN 120 mg was started the intervals
between visits were 8 weeks to assess efficacy and safety.
The initial dose of PEG-V was decreased with 50% and
later a further stepwise decrease until IGF-I levels escaped
(see results section). If IGF-I was above the upper limit of
normal the dose was increased again until IGF-I levels were
within the age adjusted normal range. If IGF-I fell below
0.5 ULN PEG-V dose was decreased. After normalization
of IGF-I during the combination treatment phase, subjects
visited our outpatient clinic every 12–16 weeks. If a peg-
visomant injection dose reached 100 mg or more, the
administration of pegvisomant was divided into 2 (equal)
dosages that were injected twice weekly.
From 2004 to 2009, IGF-I and GH concentrations were
measured by an immunometric assays (Diagnostic Products
Corporation, Los Angeles USA) and before by an immu-
noradiometric assays (Diagnostic Systems Laboratories,
Texas USA). The IGF-I age adjusted reference ranges were
used [8]. But during PEG-V treatment the GH serum levels
were not assessed.
Safety assessment included
Fasting glucose, glycosylated haemoglobin, EKG, serum
concentrations of alkaline phosphatase (AF), c-glutamyl-
transpeptidase (c-GT), alanine aminotransferase (ALT),
aspartate aminotransaminase (AST), lactate dehydrogenase
(LD), total bilirubin and change in pituitary tumor volume.
Tumor volume was assessed at baseline by MRI which was
repeated every 12 months. Change in pituitary adenoma
size was assessed by the same neuro-radiologist.
Results
LAN 120 mg was given every 4 weeks. After the second
administration of LAN 120 mg PEG-V dose was decreased
by 50% of the normal total weekly dose of the subjects.
PEG-V was increase until IGF-I normalized after 3 and/or
6 months (Table 1). Patient A was on 40 mg PEG-V, daily.
Patient’s B original dose was 30 mg a day of PEG-V. The
dose reduction of PEG-V in patient A started with a dose
decrease to twice weekly 70 mg of PEG-V. Patient B
decreased the PEG-V to twice weekly 50 mg. After
3 months patient A increased the dose to twice weekly
80 mg and patient B decreased the dose to 80 mg once
weekly. After 6 months the final dose for patient A was
twice weekly 100 mg and for patient B once weekly 60 mg
of PEG-V.
The weekly PEG-V dose reduction for patient A was
80 mg and patient B, 150 mg weekly, both with a nor-
malized IGF-I (Fig. 1).
Safety
Fasting glucose and glycosylated haemoglobin levels
increased after introduction of LAN (Table 1). In patient 1,
additional diabetic medication was necessary. Glargine up
to 48 IE was added on top of glibenclamide (5 mg b.i.d).
Patient 2 had to start diabetic medication (metformin
850 mg t.i.d.; Table 1). In these patients no transient
elevated liver enzyme tests or tumor size increase was
observed.
Discussion
We report two adequate controlled acromegaly patients
during PEG-V monotherapy. Both could also be controlled
after the conversion to combined treatment of PEG-V with
long-acting SRIF analogs. During combined treatment, a
dose reduction of PEG-V could be obtained between 80
and 150 mg weekly to keep IGF-I levels within the age-
adjusted reference range.
During long-term combined therapy the weekly mean
dose of PEG-V was 77 mg [2, 9] while with PEG-V
monotherapy a weekly mean dose of 130 mg was neces-
sary to reach an equal efficacy rate of more than 90% [4].
Data from the long-term surveillance AcroStudytm indicate
0.4
0.8
1.2
1.6
2.0
2.4
ULN
patient A
patient B
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) 
Fig. 1 1 Octreotide LAR 30 mg, 2a Pegvisomant 40 mg daily, 2b
Pegvisomant 30 mg daily, 3a and b Somatuline autosolution and
Pegvisomant
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that the mean patient on PEG-V therapy (of which around 1
out of 4 also use SRIF analogs) needs more than 21 mg of
PEG-V daily with an efficacy rate of around 60% [10].
In our 2 patients that needed high-dose PEG-V during
monotherapy, we observed dose reductions of 80 and
150 mg per week, which reflect reductions in annual costs
of around 35,000–65,000 € respectively. When we take into
consideration that high-dose SRIF analogs treatment costs
between 19,000 and 25,000 €, depending on the country,
our data indicate that in patients who need high-dose
PEG-V during monotherapy, a significant reduction in costs
can be achieved without loosing efficacy in normalizing
IGF-I levels. The ratio behind the dose reduction in PEG-V
during combined therapy of LAN and PEG-V is an increase
of about 20% in PEG-V serum levels [4, 11] and the
decrease in GH serum levels due to SRIF analog treatment.
Also, a direct and indirect inhibition of IGF-I generation of
the liver by SRIF analogs [2, 4, 11–14] has been reported.
Thus, during combined treatment PEG-V, which is a com-
petitive antagonist of the GH receptor (GHR), has less GH
to compete with, which reduces the necessary dose of
PEG-V. Moreover, experiments in rodents, observed a
decrease in the number of GHR on the liver due to a
decrease of portal insulin concentration, which is a direct
effect of SRIF analogs [12, 15, 16]. Therefore a further
reduction in PEG-V dose can be possible.
The difference in dose reduction we observed between
both patients might be explained by the expression level of
subtype of the somatostatin receptor (SSTR) on the pitui-
tary adenoma. Patient 1 might have a lower expression of
sst2 than patient B, as the efficacy of SRIF analogs in
suppressing pathological GH secretion depends on the
expression level of the sst subtypes on the pituitary ade-
noma [17]. The expression level of sst2 on human pan-
creatic beta cells is high, but there remains controversy on
the expression of sst3 and sst5 [18]. In vivo, octreotide,
mainly an sst2 agonist, decreases insulin concentration in
contrast to Pasireotide (SOM 230) [17]. Pasireotide, with
high affinity to the sst1 and sst5 as well, has as Octreotide
hyperglycemic effect. There for it unclear what the effect
of SOM 230 is on the GHR expression on the liver. The
alternative treatment with SOM 230 in patient 1 might lead
to a dose reduction since GH levels will be lower but
because of the possible higher expression of GHR a higher
dose of PEG-V could be needed. Thus it is unclear what the
net effect will be beneficial for the PEG-V dose reduction.
Finally most studies which have been conducted with SOM
230 where with diabetic patient that had an optimal control.
Therefore it is questionable if this patient would really
benefit from SOM 230.
SRIF analogs inhibits both exocrine and endocrine hor-
mone secretion and to a lesser extent neuroendocrine tumor
cell proliferation [19]. Activation of sst receptors decreases
intra-cellular c-AMP generation through the inhibition of
adenylyl cyclase. There seems to be a role of the GHRH –
cAMP signaling pathway in somatotroph tumorgenesis.
Ectopic GHRH production leads to somatotroph hyperpla-
sia, however rarely to adenoma formation [20]. GHRH
induces c-AMP via a G-protein coupled receptor, the
GHRH receptor, which induces GH production. Guanine
nucleotide-binding protein (GNAS) mutation can lead to
constitutively elevated c-AMP, protein kinase A activity,
GH synthesis and secretion [21]. About 40% of sporadic
somatotroph adenomas harbor this mutation. Although the
percentage of patients using PEG-V that develop a clinical
significant increase in tumor size is reassuring low [22, 23],
the inhibitory effects of SRIF analogs on these mechanisms
that are related to tumor growth also would suggest a more
prominent role for the combination of both SRIF analogs
and PEG-V, especially in patients with aggressive tumors
and active disease that need high dose PEG-V during
PEG-V monotherapy.
The disadvantage of SRIF analogs treatment compared
to PEG-V treatment with respect to carbohydrate metabo-
lism is clearly demonstrated here. In healthy volunteers,
administration of PEG-V did not influence the fasting
insulin and glucose or response to oral glucose loading, in
contrast with octreotide [24]. Short term combined treat-
ment resulted in a lower fasting glucose than with SRIF
analogs alone, without a change in insulin levels [11].
During long-term studies a decrease in glycosylated hae-
moglobin could be observed despite the reduction of
insulin or oral diabetic medication [2, 3]. It seems that in
the hierarchy of the beneficial effects on carbohydrate
metabolism, PEG-V as monotherapy is superior to com-
bined treatment. However, the combination is better than
SRIF analogs monotherapy.
In the past, both patients were treated with conventional
radiotherapy. This was the pre-PEG-V era. To date,
radiotherapy has become redundant from efficacy point of
view. After a mean duration of 10 years remission rates
of 50–60% are reported, but also 50–80% of subjects
develop hypopituitarism as well [25]. Radiotherapy has
some more disadvantages. A decreased quality of life has
been reported which seems to be progressive over time [26]
and radiotherapy might also increase mortality (SMR 2.68)
mainly due to cerebrovascular mortality [27]. Our patients
already showed some long-term side effects of radiother-
apy as both have hypopituitarism. Cerebrovascular acci-
dents have not occurred to date.
These two cases are different from our previous reports,
because these two patients were previously treated con-
trolled with PEG-V daily monotherapy. Our previous
studies included patients on SRIF analogs that still had an
elevated IGF-I and therefore we did not have a direct
comparison for dose reduction of PEG-V.
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In this case-study we start immediately with high-dose
SRIF analogs treatment and we reduce weekly dose of
pegvisomant by 50%. After 3 and 6 months, the PEG-V
can be adjusted according to the serum IGF-I levels, If
elevated, a higher weekly dose is necessary, while in case
of normal IGF-I levels, one could further reduce the
PEG-V dosages to find the lowest effective dose.
In conclusion, these two case-reports show that a dose
reduction in PEG-V is possible after the addition of a
monthly high dose SRIF analogs. This might significantly
reduce the annual costs. However, deterioration in the
carbohydrate metabolism should be taken into account.
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